Cargando…

Current Perspectives on HIV-1 Antiretroviral Drug Resistance

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyidogan, Pinar, Anderson, Karen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213579/
https://www.ncbi.nlm.nih.gov/pubmed/25341668
http://dx.doi.org/10.3390/v6104095
_version_ 1782341845892726784
author Iyidogan, Pinar
Anderson, Karen S.
author_facet Iyidogan, Pinar
Anderson, Karen S.
author_sort Iyidogan, Pinar
collection PubMed
description Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.
format Online
Article
Text
id pubmed-4213579
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42135792014-10-31 Current Perspectives on HIV-1 Antiretroviral Drug Resistance Iyidogan, Pinar Anderson, Karen S. Viruses Review Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly. MDPI 2014-10-24 /pmc/articles/PMC4213579/ /pubmed/25341668 http://dx.doi.org/10.3390/v6104095 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iyidogan, Pinar
Anderson, Karen S.
Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title_full Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title_fullStr Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title_full_unstemmed Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title_short Current Perspectives on HIV-1 Antiretroviral Drug Resistance
title_sort current perspectives on hiv-1 antiretroviral drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213579/
https://www.ncbi.nlm.nih.gov/pubmed/25341668
http://dx.doi.org/10.3390/v6104095
work_keys_str_mv AT iyidoganpinar currentperspectivesonhiv1antiretroviraldrugresistance
AT andersonkarens currentperspectivesonhiv1antiretroviraldrugresistance